Clinical Considerations in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Host: Ana Ferreira Castro, MD
Guest: Gilberto de Castro Junior, MD, PhD
Guest: Zujun Li, MD
Guest: Ricard Mesia, MD, PhD
Squamous cell carcinoma of the head and neck is one of the most common cancers worldwide, with over 500,000 new cases and 380,000 deaths annually. In this regard, the poor outcomes associated with recurrent/metastatic squamous cell carcinoma of the head and neck represent a significant unmet medical need. For these patients, first-line pharmacologic therapy includes chemotherapy, targeted therapies, and immunotherapy, often in combination. Nonetheless, treatment selection is widely recognized as difficult due to complex patient and disease factors.